Novo Nordisk recently announced FDA approval of an expanded pediatric indication for Tresiba, meaning that the basal insulin can now be used to treat people with type 1 and type 2 diabetes as young as age one. The label update is based on data from the BEGIN YOUNG 1 trial, which showed Tresiba is safe and effective when used in children with type 1 diabetes.